Title: Elucidating mechanisms of toxicity using phenotypic data from primary human cell systems--a chemical biology approach for thrombosis-related side effects.
Journal: International journal of molecular sciences 20150101
Title: Conformation-specific effects of Raf kinase inhibitors.
Journal: Journal of medicinal chemistry 20120913
Title: Comprehensive analysis of kinase inhibitor selectivity.
Journal: Nature biotechnology 20111030
Title: The discovery of furo[2,3-c]pyridine-based indanone oximes as potent and selective B-Raf inhibitors.
Journal: Bioorganic & medicinal chemistry letters 20110215
Title: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.
Journal: Nature 20100318
Title: Disposition of GDC-0879, a B-RAF kinase inhibitor in preclinical species.
Journal: Xenobiotica; the fate of foreign compounds in biological systems 20090901
Title: Pharmacodynamics of 2-[4-[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl]-3-(pyridine-4-yl)-1H-pyrazol-1-yl]ethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy.
Journal: The Journal of pharmacology and experimental therapeutics 20090401
Title: Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated kinase/mitogen-activated protein kinase pathway suppression.
Journal: Cancer research 20090401
Title: Potent and selective pyrazole-based inhibitors of B-Raf kinase.
Journal: Bioorganic & medicinal chemistry letters 20080815
Title: Hansen JD, et al. Potent and selective pyrazole-based inhibitors of B-Raf kinase. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4692-5.
Title: Wong H, et al. Pharmacodynamics of 2--[(1E)-1-(hydroxyimino)-2,3-dihydro-1H-inden-5-yl-3-(pyridine-4-yl)-1H-pyrazol-1-ylethan-1-ol (GDC-0879), a potent and selective B-Raf kinase inhibitor: understanding relationships between systemic concentrations, phosphorylated mitogen-activated protein kinase kinase 1 inhibition, and efficacy. J Pharmacol Exp Ther. 2009 Apr;329(1):360-7.
